AMGN Jumps After Win In Sjögren’s Disease Trial As Citi Flags ‘Open Questions’
Amgen (AMGN) shares rose 4% after reporting positive late-stage trial results for dazodalibep in treating systemic Sjögren’s disease, a condition with no approved therapy. The trial showed significant improvement in disease intensity. Citi noted positive results but awaits more details, maintaining a Neutral rating and $405 price target. AMGN is up 25% year-to-date.
How this was made
The 30-second read
Why it matters
The trial's positive topline results could accelerate regulatory discussions and increase Amgen's valuation in the I&I space.
Market read
Amgen's stock jumped ~5% on the news, indicating immediate market relevance and potential for further moves as data matures.
What to watch
Potential safety signals and comparative advantage versus Novartis and J&J pipelines could temper enthusiasm.
Background
Amgen acquired Horizon Therapeutics in 2023, gaining the dazodalibep asset now in late-stage testing.
Ticker impact
Amgen reported positive late-stage trial results for dazodalibep in systemic Sjögren’s disease, driving a 4-5% stock rise.
upward pressure, potential 3-5% gain in the short term
First late-stage win in a disease with no approved therapy, coupled with a notable intraday rally, suggests material market impact.
Market effects
Strengthens the immunology and inflammation sector, may lift peers developing similar therapies.
U.S. biotech market sees modest uplift from the news.
Highlights ongoing demand for autoimmune disease treatments worldwide.
Counterpoint
Citi notes open questions on efficacy magnitude and competitive profile; investors may wait for full data before committing.
Key entities
- companyAmgen
Biopharma company reporting trial results.
- analystCiti
Provided neutral rating and price target.
